Policy statement - Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia

Pediatrics

Volumn 126, Issue 4, 2010, Pages 800-808

  Watterberg, Kristi L ^a   Papile, Lu Ann ^a   Adamkin, David H ^a   Baley, Jill E ^a   Bhutani, Vinod K ^a   Carlo, Waldemar A ^a   Kumar, Praveen ^a   Polin, Richard A ^a   Tan, Rosemarie C ^a   Wang, Kasper S ^a  

^a NONE

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease; Dexamethasone; Glucocorticoid; Preterm infant

Indexed keywords

BECLOMETASONE; DEXAMETHASONE; HYDROCORTISONE; PLACEBO; GLUCOCORTICOID;

CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; FOLLOW UP; HUMAN; LOW DRUG DOSE; LUNG DYSPLASIA; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; BRONCHOPULMONARY DYSPLASIA; CHILD DEVELOPMENT; INFANT, PREMATURE, DISEASES; NEWBORN; PRACTICE GUIDELINE;

BRONCHOPULMONARY DYSPLASIA; CHILD DEVELOPMENT; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES;

EID: 77957720463     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-1534     Document Type: Review

References (74)

1. Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB; COIN Trial Investigators. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med. 2008;358(7):700-708 (Pubitemid 351240749)
2. Walsh M, Laptook A, Kazzi SN, et al. National Institute of Child Health and Human Development Neonatal Research Network. A cluster-randomized trial of benchmarking and multimodal quality improvement to improve rates of survival free of bronchopulmonary dysplasia for infants with birth weights of less than 1250 grams. 2007;119(5):876-890
3. Vohr BR, Wright LL, Poole WK, McDonald SA. Neurodevelopmental outcomes of extremely low birth weight infants <32 weeks' gestation between 1993 and 1998. Pediatrics. 2005;116(3):635-643
4. Kobaly K, Schluchter M, Minich N, et al. Outcomes of extremely low birth weight (<1 kg) and extremely low gestational age (<28 weeks) infants with bronchopulmonary dysplasia: effects of practice changes in 2000 to 2003. Pediatrics. 2008;121(1):73-81
5. American Academy of Pediatrics, Committee on Fetus and Newborn; Canadian Paediatric Society, Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002; 109(2):330-338
6. Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee SK, Ohlsson A. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics. 2006;118(5): Available at: www.pediatrics.org/cgi/ content/full/118/5/e1328
7. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000;83(3):F177-F181
8. Yoder BA, Harrison M, Clark RH. Timerelated changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics. 2009;124(2):673-679
9. Barrington KJ. The adverse neurodevelopmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001;1:1
10. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001146
11. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001144
12. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001145
13. Halliday HL, Ehrenkranz RA, Doyle LW. Early (<8 days) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009;(1):CD001146
14. Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009;(1):CD001145
15. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005;115(3):655-661
16. Onland W, Offringa M, De Jaegere AP, van Kaam AH. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics. 2009;123(1):367-377
17. McEvoy C, Bowling S, Williamson K, McGaw P, Durand M. Randomized, double-blinded trial of low-dose dexamethasone: II. Functional residual capacity and pulmonary outcome in very low birth weight infants at risk for bronchopulmonary dysplasia. Pediatr Pulmonol. 2004;38(1)55-63
18. Odd DE, Armstrong DL, Teele RL, Kuschel CA, Harding JE. A randomized trial of two dexamethasone regimens to reduce side-effects in infants treated for chronic lung disease of prematurity. J Paediatr Child Health. 2004;40(5-6):282-289
19. Malloy CA, Hilal K, Rizvi Z Weiss M Muraskas JK. A prospective, randomized, double-masked trial comparing low dose to conventional dose dexamethasone in neonatal chronic lung disease. Internet J Pediatr Neonatol. 2005; 5(1). Available at: www.ispub.com/ostia/index.php?xmlPrinter= true&xmlFilePath=journals/ijpn/vol5n1/dexamethasone.xml. Accessed March 16, 2010
20. Walther FJ, Findlay RD, Durand M. Adrenal suppression and extubation rate after moderately early low-dose dexamethasone therapy in very preterm infants. Early Hum Dev. 2003;74(1):37-45
21. Anttila E, Peltoniemi O, Haumont D, et al. Early neonatal dexamethasone treatment for prevention of bronchopulmonary dysplasia: randomised trial and meta-analysis evaluating the duration of dexamethasone therapy. Eur J Pediatr. 2005;164(8):472-481 (Pubitemid 41073812)
22. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB; DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006;117(1):75-83 (Pubitemid 46050522)
23. Rozycki HJ, Byron PR, Elliott GR, Carroll T, Gutcher GR. Randomized controlled trial of three different doses of aerosol beclomethasone versus systemic dexamethasone to promote extubation in ventilated premature infants. Pediatr Pulmonol. 2003;35(5):375-383
24. Armstrong DL, Penrice J, Bloomfield FH, Knight DB, Dezoete JA, Harding JE. Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2002;86(2):F102-F107
25. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB; DART Study Investigators. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics. 2007;119(4):716-721
26. Stark AR, Carlo W, Vohr BR, et al. NICHD Neonatal Research Network. Neurodevelopmental outcome and growth at 18-22 months [abstract]. Pediatr Res. 2001;49:388A
27. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. A three year follow up of preterm infants after moderately early treatment with dexamethasone. Arch Dis Child Fetal Neonatal Ed. 2002;87(1):F55-F58 (Pubitemid 34753801)
28. Wilson TT, Waters L, Patterson CC, et al. Neurodevelopmental and respiratory follow-up results at 7 years for children from the United Kingdom and Ireland enrolled in a randomized trial of early and late postnatal corticosteroid treatment, systemic and inhaled. The Open Study of Early Corticosteroid Treatment. Pediatrics. 2006;117(6):2196-2205
29. Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350(13):1304-1313
30. O'Shea TM, Washburn LK, Nixon PA, Goldstein DJ. Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age. Pediatrics. 2007; 120(3): 594-602
31. Gross SJ, Anbar RD, Mettelman BB. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics. 2005;115(3):681-687
32. Jones RA; Collaborative Dexamethasone Trial Follow-up Group. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13-to 17-year follow-up study: I. Neurologic, psychological, and educational outcomes. Pediatrics. 2005;116(2):370-378
33. Wilson-Costello D, Walsh MC, Langer JC, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants. Pediatrics. 2009;123(3):Available at: www.pediatrics.org/cgi/content/full/123/3/e430
34. Murphy BP, Inder TE, Huppi PS, et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics. 2001;107(2):217-221
35. Parikh NA, Lasky RE, Kennedy KA, et al. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics. 2007;119(2):265-272
36. O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999; 104(1 pt 1):15-21
37. Noble-Jamieson CM, Regev R, Silverman M. Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications. Eur J Pediatr. 1989;148(4):365-367 (Pubitemid 19031049)
38. Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999;104(6):1258-1263
39. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004;114(6):1649-1657
40. Peltoniemi O, Kari MA, Heinonen K, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr. 2005;146(5):632-637
41. Bonsante F, Latorre G, Iacobelli S, et al. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology. 2007;91(4):217-221
42. Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics. 1995;95(1):120-125
43. Huysman MW, Hokken-Koelega AC, De Ridder MA, Sauer PJ. Adrenal function in sick very preterm infants. Pediatr Res. 2000;48(5):629-633
44. Watterberg KL, Scott SM, Backstrom C, Gifford KL, Cook KL. Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. Pediatrics. 2000;105(2):320-324
45. Watterberg KL, Gerdes JS, Cook, KL. Impaired glucocorticoid synthesis in premature infants developing chronic lung disease. Pediatr Res. 2001;50(2):190-195 (Pubitemid 32701191)
46. Nykänen P, Anttila E, Heinonen K, Hallman M, Voutilainen R. Early hypoadrenalism in premature infants at risk for bronchopulmonary dysplasia or death. Acta Paediatr. 2007;96(11):1600-1605
47. Garland JS, Alex CP, Pauly TH, et al. A threeday course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics. 1999;104(1 pt 1):91-99
48. Stark AR, Carlo WA, Tyson JE, et al; National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. N Engl J Med. 2001;344(2):95-101
49. Watterberg KL, Shaffer ML, Mishefske MJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics. 2007;120(1):40-48 (Pubitemid 47036239)
50. Peltoniemi OM, Lano A, Puosi R, et al; Neonatal Hydrocortisone Working Group. Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology. 2009;95(3):240-247
51. Baden M, Bauer CR, Colle E, Klein G, Taeusch HW Jr, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics. 1972;50(4):526-534
52. Biswas S, Buffery J, Enoch H, Bland M, Markiewicz M, Walters D. Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks gestation: results of the THORN trial - thyroid hormone replacement in neonates. Pediatr Res. 2003;53(1):48-56
53. van der Heide-Jalving M, Kamphuis PJ, van der Laan MJ, et al. Short-and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr. 2003; 92(7): 827-835
54. Karemaker R, Heijnen CJ, Veen S, et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res. 2006;60(6):745-750
55. Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics. 2005;116(1):1-7
56. Rademaker KJ, Uiterwaal CS, Groenendaal F, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr. 2007;150(4):351-357
57. 1H-MRS of the hippocampus and short-term memory at school age in preterm born children. Pediatr Res. 2006;59(2):309-313
58. Karemaker R, Kavelaars A, ter Wolbeek M, et al. Neonatal dexamethasone treatment for chronic lung disease of prematurity alters the hypothalamus-pituitary-adrenal axis and immune system activity at school age. Pediatrics. 2008;121(4): Available at: www.pediatrics.org/cgi/content/full/121/ 4/e870
59. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev. 2007;(4):CD002057
60. Shah V, Ohlsson A, Halliday HL, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2007;(4):CD001969
61. Howard E. Reductions in size and total DNA of cerebrum and cerebellum in adult mice after corticosterone treatment in infancy. Exp Neurol. 1968;22(2):191-208
62. Howard E, Benjamin JA. DNA, ganglioside and sulfatide in brains of rats given corticosterone in infancy, with an estimate of cell loss during development. Brain Res. 1975;92(1):73-87
63. Taeusch HW Jr, Wang NS, Baden M, Bauer C, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome: II. Pathology. Pediatrics. 1973;52(6):850-854
64. Fitzhardinge PM, Eisen A, Lejtenyi C, Metrakos K, Ramsay M. Sequelae of early steroid administration to the newborn infant. Pediatrics. 1974;53(6):877-883
65. Williams GH, Dluhy RG. Diseases of the adrenal cortex. In:Fauci AS Braunwald E, Isselbacher KJ et al, eds. Harrison's Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill; 1998:2035-2057
66. Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids: effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977;63(2):200-207
67. Goldman-Rakic PS. Development of cortical circuitry and cognitive function. Child Dev. 1987;58(3):601-622
68. Isaacs EB, Lucas A, Chong WK, et al. Hippocampal volume and everyday memory in children of very low birth weight. Pediatr Res. 2000;47(6):713-720
69. McEwen BS. The brain is an important target of adrenal steroid actions: a comparison of synthetic and natural steroids. Ann N Y Acad Sci. 1997;823:201-213
70. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998; 19(3):269-301 (Pubitemid 29117816)
71. Sloviter RS, Sollas AL, Neubort S. Hippocampal dentate granule cell degeneration after adrenalectomy in the rat is not reversed by dexamethasone. Brain Res. 1995;682(1-2):227-230
72. Hassan AH, von Rosenstiel P, Patchev VK, Holsboer F, Almeida OF. Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol. 1996;140(1):43-52
73. Huang CC, Lin HR, Liang YC, Hsu KS. Effects of neonatal corticosteroid treatment on hippocampal synaptic function. Pediatr Res. 2007;62(3):267-270
74. Thompson DK, Wood SJ, Doyle LW, et al. Neonate hippocampal volumes: prematurity, perinatal predictors, and 2-year outcome. Ann Neurol. 2008;63(5):642-651